Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

CaroGen partners with BioCentriq re hepatitis B

CaroGen Corporation has selected BioCentriq™ as their partner for clinical manufacturing to support Phase 1 clinical trials of its lead immunotherapy candidate, CARG-201, which has...

| By Kelley Gipson

UConn receives record research grant from NSF

The U.S. National Science Foundation (NSF) has awarded the University of Connecticut a $40 million research grant award, the largest in the University’s history, to...

| By Kelley Gipson

MannKind adding Danbury jobs re Tyvaso DPI

MannKind says that its Danbury facility is hiring more than 100 people and is preparing essential equipment and production lines ahead of an expected commercial launch....

| By Kelley Gipson

SpringWorks re glioma, neurofibromas, myeloma

SpringWorks Therapeutics reports the initiation of a Phase 1/2 clinical trial to evaluate mirdametinib, an investigational MEK inhibitor, for the treatment of children, adolescents, and...

| By Kelley Gipson

Tesseract pilots AI-enabled eye-scanning technology

A Guilford-based startup, Tesseract Health, hopes to use novel multidimensional sensors and artificial intelligence to take an “eye selfie,” allowing doctors to peer into the back of...

| By Kelley Gipson

Study published of Cybrexa candidate CBX-12

A peer-reviewed study of CBX-12, the lead candidate of Cybrexa Therapeutics, has been published. The study found that CBX-12 displays pH selectivity, stability in plasma and...

| By Kelley Gipson

Cybrexa, IsoPlexis add to management strength

Cybrexa Therapeutics, an oncology-focused biotechnology company based in New Haven, has appointed pharmaceutical and financial services veteran Stephen Basso to serve as its chief financial...

| By Kelley Gipson

FDA approves expanded use of Alexion’s ULTOMIRIS®

Alexion Pharmaceuticals reports that the FDA has approved the expanded use of ULTOMIRIS® (ravulizumab-cwvz) to include children (one month of age and older) and adolescents with...